@article {8043,
	title = {The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy},
	journal = {European Journal of Gynaecological Oncology},
	volume = {25},
	year = {2004},
	note = {Cited By :23Export Date: 21 February 2017},
	month = {2004},
	pages = {225 - 229},
	abstract = {Purpose: To evaluate the prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erbB-2 and cathepsin-D in epithelial ovarian cancer (EOC). Methods: We analyzed 100 patients with ovarian carcinoma, FIGO Stage IC-IV who underwent primary cytoreductive surgery and received adjuvant chemotherapy with cyclophosphamide and a platinum analogue (CP) (n = 46) or paclitaxel and a platinum analogue (TP) (n = 54). Immunohistochemical expression was studied on paraffin-embedded tissue from the primary tumor. Results: After a median follow-up of 55 months median progression-free survival (PFS) and overall survival (OS) were 16 and 41 months, respectively. Positive bcl-2 staining and absence of cathepsin-D expression were associated with an increased complete response rate in the CP group (p = 0.011 and p = 0.003) but not in the TP group. PFS and OS were not associated with the expression of any of the markers studied. FIGO stage (p = 0.006) and histology (p = 0.047) were the only independent prognostic factors for survival. Conclusion: Bcl2 and cathepsin D expression are associated with response to CP but not TP chemotherapy. P53, bcl-2, c-erb B-2 and cathepsin D expression was not correlated with PFS and OS in our study.},
	keywords = {Bcl-2, c-erb B-2, Cathepsins, Ovarian cancer, p53, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-1442351945\&partnerID=40\&md5=5473b1e1cec2a0f2860eec58ce290d00},
	author = {Protopapas, A. and Diakomanolis, E. and Bamias, A. and Milingos, S. and Markaki, S. and Papadimitriou, C. and Dimopoulos, A.-M. and Michalas, S.}
}
